

NCT ID	NCT04963283
Title	Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
Phase	Phase 2
Date Added	2021-07-15
Location	Colorado, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Cabozantinib, Nivolumab
Tags	MSS/ MMRp
NCT ID	NCT04948034
Title	The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE)
Phase	Phase 2
Date Added	2021-07-01
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Fruquintinib, Tislelizumab
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT04940546
Title	Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in pMMR/MSS CRLM Patients
Phase	Phase 1, Phase 2
Date Added	2021-06-25
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Bevacizumab, capecitabine, oxaliplatin, Sintilimab
Tags	MSS/ MMRp
NCT ID	NCT04895709
Title	A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab in Participants With Advanced Solid Tumors
Phase	Phase 1, Phase 2
Date Added	2021-05-20
Location	California, United States Iowa, United States New Jersey, United States New York, United States Oregon, United States Tennessee, United States Texas, United States Australia Canada Germany Israel Italy Japan Spain
Prior IO Allowed	Yes
CRC-directed	Yes

Status	Recruiting
Drugs	BMS-936558-01, BMS-986340
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT04895722
Title	Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008)
Phase	Phase 2
Date Added	2021-05-20
Location	Florida, United States Georgia, United States Illinois, United States New York, United States Pennsylvania, United States Tennessee, United States Texas, United States Washington, United States Belgium Canada Colombia Costa Rica Denmark Estonia France Germany Greece Guatemala Hungary Italy Korea, Republic of Lithuania Netherlands Poland Romania Russian Federation Spain Turkey United Kingdom
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Favezelimab/Pembrolizumab, Pembrolizumab/Quavonlimab, pembrolizumab/vibostolimab coformulation, Keytruda
Tags	MSI-H/ MMRd
NCT ID	NCT04874259
Title	LT for Unresectable Colorectal Liver Metastasis
Phase	Not Applicable
Date Added	2021-05-05
Location	Korea, Republic of
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT04866862
Title	Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer

Phase	Phase 2
Date Added	2021-04-30
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Combination of Fruquintinib and Camrelizumab
Tags	MSS/ MMRp
NCT ID	NCT04853017
Title	ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (AMPLIFY-201)
Phase	Phase 1
Date Added	2021-04-21
Location	California, United States Colorado, United States Iowa, United States Massachusetts, United States Missouri, United States New York, United States Tennessee, United States Texas, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT04793958
Title	Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
Phase	Phase 3
Date Added	2021-03-11

Location	Alabama, United States
	Arizona, United States
	Arkansas, United States
	California, United States
	Colorado, United States
	Connecticut, United States
	Florida, United States
	Georgia, United States
	Illinois, United States
	Indiana, United States
	Iowa, United States
	Louisiana, United States
	Maryland, United States
	Massachusetts, United States
	Michigan, United States
	Minnesota, United States
	Missouri, United States
	Nebraska, United States
	Nevada, United States
	New Jersey, United States
	New York, United States
	North Carolina, United States
	Ohio, United States
	Oklahoma, United States
	Pennsylvania, United States
	South Carolina, United States
	Tennessee, United States
	Texas, United States
	Utah, United States
	Virginia, United States
	Washington, United States
	West Virginia, United States
	Wisconsin, United States
	Argentina
	Australia
	Austria
	Belgium
	Brazil
	Canada
	China
	Colombia
	Czechia
	Denmark
	Finland
	France
	Germany
	Greece
	Hong Kong
	Ireland
	Italy
	Korea, Republic of
	Malaysia
	Mexico
	Netherlands
	Poland
	Portugal
	Puerto Rico
	Romania
	Singapore
	Spain
	Taiwan
	Thailand
	Ukraine
	United Kingdom
Prior IO Allowed	Yes
CRC-directed	Yes

Status	Active, not recruiting
Drugs	cetuximab, FOLFIRI Regimen, mFOLFOX6 Regimen, MRTX849
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT04776148
Title	Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)
Phase	Phase 3
Date Added	2021-03-01
Location	California, United States Georgia, United States Illinois, United States Maryland, United States Michigan, United States Montana, United States Oregon, United States Pennsylvania, United States Virginia, United States Washington, United States Argentina Australia Canada China Denmark Germany Israel Japan Korea, Republic of Russian Federation Spain Taiwan Turkey United Kingdom
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Lenvatinib, Pembrolizumab, Regorafenib, TAS-102 (trifluridine and tipiracil)
Tags	MSS/ MMRp